{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["202(5)"],"submitter":["Sollner JF"],"funding":["The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and enrolling centers."],"pubmed_abstract":["<h4>Purpose</h4>We investigated whether a 52-gene signature was associated with transplant-free survival and other clinically meaningful outcomes in patients with idiopathic pulmonary fibrosis (IPF) in the IPF-PRO Registry, which enrolled patients who were and were not taking antifibrotic therapy.<h4>Methods</h4>The 52-gene risk signature was implemented to classify patients as being at \"high risk\" or \"low risk\" of disease progression and mortality. Transplant-free survival and other outcomes were compared between patients with a low-risk versus high-risk signature.<h4>Results</h4>The 52-gene signature classified 159 patients as at low risk and 86 as at high risk; in these groups, respectively, 56.6% and 51.2% used antifibrotic therapy at enrollment. Among those taking antifibrotic therapy"],"journal":["Lung"],"pagination":["595-599"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11427488"],"repository":["biostudies-literature"],"pubmed_title":["Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy."],"pmcid":["PMC11427488"],"pubmed_authors":["Salisbury ML","Vinisko R","Todd JL","IPF-PRO Registry investigators","Leonard TB","Schlange T","Bentink S","Neely ML","Patel NM","Sollner JF","Hesslinger C"],"additional_accession":[]},"is_claimable":false,"name":"Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy.","description":"<h4>Purpose</h4>We investigated whether a 52-gene signature was associated with transplant-free survival and other clinically meaningful outcomes in patients with idiopathic pulmonary fibrosis (IPF) in the IPF-PRO Registry, which enrolled patients who were and were not taking antifibrotic therapy.<h4>Methods</h4>The 52-gene risk signature was implemented to classify patients as being at \"high risk\" or \"low risk\" of disease progression and mortality. Transplant-free survival and other outcomes were compared between patients with a low-risk versus high-risk signature.<h4>Results</h4>The 52-gene signature classified 159 patients as at low risk and 86 as at high risk; in these groups, respectively, 56.6% and 51.2% used antifibrotic therapy at enrollment. Among those taking antifibrotic therapy","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-02T06:28:29.333Z","creation":"2025-04-06T16:10:06.286Z"},"accession":"S-EPMC11427488","cross_references":{"pubmed":["39242435"],"doi":["10.1007/s00408-024-00742-x"]}}